TAK-828F is a potent, selective, and orally available retinoic acid receptor-related orphan receptor γt (RORγt) inverse agonist (binding IC50=1.9 nM, reporter gene IC50=6.1 nM). TAK-828F shows excellent ROR isoforms selectivity (>5000-fold selectivity aga

Target Protein-binding moiety 6 hydrochloride is a compound that binds to BRD9, and used for inhibiting BRD9 activity, based on PROTAC.

TB500-2 is one of the TB500 metabolites. TB500 is a synthetic version of an active region of thymosin β4. TB500 is claimed to promote endothelial cell differentiation, angiogenesis in dermal tissues, keratinocyte migration, collagen deposition and decreas

The less active enantiomer of GNE-140, inhibits LDHA activity (18-fold less potent that (R)-GNE-140).

TM-25659 is a TAZ modulator. Anti-osteoporotic and anti-obesity activities.

Trk-IN-4 is a potent pan-Trk inhibitor in cell-based assays with IC50s of 1.9 nM, 2.6 nM and 1.1 nM for TrkA, TrkB and TrkC, respectively. Anti-hyperalgesic effect.

Tubulin inhibitor 1 is a tubulin inhibitor, occupying the colchicine binding site, inhibits tubulin polymerization. Tubulin inhibitor 1 shows potent anti-tumor activity, casues cellular mitotic arrest in the G2/M phase, and induces cellular apoptosis.

XMD-18-42 is a NUAK1-sepcific inhibitor.

Y06036 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with Kd value of 82 nM. Antitumor activity.

Y06137 is a potent and selective BET inhibitor, which binds to the BRD4(1) bromodomain with a Kd of 81 nM. Antitumor activity.

Z-LEHD-FMK is a cell-permeable, competitive and irreversible inhibitor of enzyme caspase-9, which helps in cell survival.

BAY 61-3606 is a potent, ATP-competitive, reversible, and highly selective inhibitor of Syk tyrosine kinase with Ki of 7.5 nM, displays no inhibitory effect against Btk, Fyn, Itk, Lyn, and Src.

JPH203, also known as KYT-0353, is a potent and selective LAT1 selective ( L-type amino acid transporter 1) inhibitor. JPH203 can very potently inhibit l-leucine uptake. JPH203 inhibits YD-38 cell growth. JPH203 up-regulated the population of apoptotic Y

BL-AD008 (BL-AD 008) is a novel small molecule, dual-target activator targeting AMPK/ZIPK; demonstrates remarkable anti-proliferative activities toward cervical cancer cells and could induce apoptosis by death-receptor and mitochondrial pathways; also sho

A potent and selective VEGFR2 (KDR) inhibitor with IC50 of 40 nM.

>98%,Standard References

>98%,Standard References

>98%,Standard References

>98%,Standard References

>98%,Standard References

>98%,Standard References

>98%,Standard References

>98%,Standard References

>98%,Standard References

>98%,Standard References

>98%,Standard References

>98%,Standard References

>98%,Standard References

>98%,Standard References